An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants diagnosed with moderately to severely active Ulcerative colitis (UC).
Participants who are within 14 days from the commencement of Rinvoq treatment for UC.
Participants who are administered the first dose of Rinvoq for UC after approval for UC in Japan.
You may not be if
Participants currently participating in registrational clinical trial.
Participants for whom Rinvoq is contraindicated.
Participants that have been previously exposed to Rinvoq.
Clareo Health | An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
